Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors
esmo - Findings from the LITESPARK-011 study
AI Summary: A Phase 3 trial shows belzutifan combined with lenvatinib improves progression-free survival compared with cabozantinib in patients with advanced renal cell carcinoma who progressed on PD‑1/PD‑L1 inhibitors. The result offers a new sequenced treatment option and shifts the landscape for post–checkpoint inhibitor RCC management.